Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up – Time to Buy?

Rapport Therapeutics (NASDAQ:RAPP)’s stock price gapped up prior to trading on Monday . The stock had previously closed at $16.13, but opened at $16.88. Rapport Therapeutics shares last traded at $15.98, with a volume of 2,967 shares trading hands.

Rapport Therapeutics Trading Down 4.2 %

The company has a 50 day moving average price of $17.08 and a 200 day moving average price of $20.27.

Hedge Funds Weigh In On Rapport Therapeutics

A number of large investors have recently made changes to their positions in the stock. FMR LLC increased its holdings in Rapport Therapeutics by 10.1% in the third quarter. FMR LLC now owns 5,486,468 shares of the company’s stock valued at $112,363,000 after buying an additional 503,117 shares in the last quarter. Geode Capital Management LLC purchased a new position in Rapport Therapeutics in the 3rd quarter valued at approximately $4,133,000. Millennium Management LLC acquired a new position in Rapport Therapeutics during the second quarter worth $2,716,000. Charles Schwab Investment Management Inc. acquired a new stake in Rapport Therapeutics in the third quarter valued at $1,498,000. Finally, Jennison Associates LLC purchased a new stake in shares of Rapport Therapeutics in the 4th quarter worth about $1,105,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.